Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
The use of adeno-associated virus (AAV) as a gene therapy vector has been approved recently for clinical use and has demonstrated efficacy in a growing number of clinical trials. However, the safety of AAV as a vector has been challenged by a single study that documented hepatocellular carcinoma (HCC) after AAV gene delivery in mice. Most studies have not noted genotoxicity following AAV-mediated gene delivery; therefore, the possibility that there is an association between AAV and HCC is controversial. Here, we performed a comprehensive study of HCC in a large number of mice following therapeutic AAV gene delivery. Using a sensitive high-throughput integration site-capture technique and global expressional analysis, we found that AAV integration into the RNA imprinted and accumulated in nucleus (Rian) locus, and the resulting overexpression of proximal microRNAs and retrotransposon-like 1 (Rtl1) were associated with HCC. In addition, we demonstrated that the AAV vector dose, enhancer/promoter selection, and the timing of gene delivery are all critical factors for determining HCC incidence after AAV gene delivery. Together, our results define aspects of AAV-mediated gene therapy that influence genotoxicity and suggest that these features should be considered for design of both safer AAV vectors and gene therapy studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“preclinical data suggest AAV integration events occur in a dose-dependent manner with a preference for integration at sites of active transcription, tissue-specific promoters are protective against oncogenesis.178, 179, 180”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [179]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cutadapt removes adapter sequences from high-throughput sequencing reads
Martin, M. (2011) · EMBnet.journal · doi:10.14806/ej.17.1.200 · Cited by 33,889 · cited 1×
“GCGCGCTCGCTCG-3′) were trimmed by cutadapt (57).”
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400 · cited 2×
“Mouse BLAT (61, 62) (assembly December 2011 Genome Reference Consortium Mouse Build 38/mm10) was used to align the resultant sequence to the murine genome.”
<tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool
Kent, W. J. (2002) · Genome Research · doi:10.1101/gr.229202 · Cited by 8,480 · cited 2×
“Mouse BLAT (61, 62) (assembly December 2011 Genome Reference Consortium Mouse Build 38/mm10) was used to align the resultant sequence to the murine genome.”
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 1×
“To investigate this possibility, we developed a vector, AAV8-hAAT-synMUT, modeled on a AAV vector that had been administered to human subjects with hemophilia and did not cause genotoxicity in mice (13, 33).”
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“In fact, there are multiple human AAV gene therapy trials around the world that have been completed, are accruing participants, or are in preparation (4), and recent studies using AAV to treat 3 genetic disorders have been regarded as successful (5–8).”
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“The most relevant example is the failure of animal studies to predict the increased risk for the development of leukemia after retroviral gene therapy for X-linked severe combined immunity deficiency (45).”
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 2×
“…the use of a more hepatotrophic serotype, such as AAV8 compared with AAV2, led to an increase in the rate of HCC. Additionally, the use of distinct capsids to pseudotype AAV vectors (48), such as serotypes 8 and 9, confers distinct patterns of tissue troph-ism in wild-type and disease states (49).”
Research works printed but not linked: 1
- Martin, 2011, EMBnetJ., 17
Cited by
Items 101–200 of 422
Helper-dependent adenoviral vectors for liver-directed gene therapy of primary hyperoxaluria type 1
Castello, R., Borzone, R., D’Aria, S., Annunziata, P., Piccolo, P., & Brunetti‐Pierri, N. (2015) · Gene Therapy · doi:10.1038/gt.2015.107 · Cited by 52
Organic acidurias: Major gaps, new challenges, and a yet unfulfilled promise
Dimitrov, B., Molema, F., Williams, M., Schmiesing, J., Mühlhausen, C., Baumgartner, M. R., Schumann, A., & Kölker, S. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12254 · Cited by 54
“For example, it was demonstrated that the AAV vector dose, enhancer/promotor selection, and the timing of gene delivery are critical factors that determine the risk of developing hepatocellular carcinoma after AAV gene delivery to the liver.(110) Furthermore, both approaches will or are likely to result in a transient…”
BackgroundFerla, R., Alliegro, M., Dell’Anno, M., Nusco, E., Cullen, J. M., Smith, S. N., Wolfsberg, T. G., O’Donnell, P., Wang, P., Nguyen, A., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.11.015 · Cited by 51
“Genomic locations (UCSCGenomeBrowser, GenomeReferenceConsortiumMouse Build 38 December 2012, mm10) on Chromosome 12 of rAAVHCC integrations arising only from vectors with TBG promoter.(5,6,13,20) www.”
BackgroundMethodResultSelf-citationModern therapeutic approaches to liver-related disorders
Gardin, A., Remih, K., Gonzales, E. M., Andersson, E. R., & Strnad, P. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.015 · Cited by 52
Gene therapy: principles, challenges and use in clinical practice
Ay, C., & Reinisch, A. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02368-8 · Cited by 61
“…that pathogenic AAV integration events might actively contribute to hepatocellular cancer development, although potential genotoxic events are highly dependent on factors including AAV integration preferences, vector design, vector dose and, in particular, recipient age at AAV injection [41–43].”
Adipose Tissue: An Emerging Target for Adeno-associated Viral Vectors
Bates, R., Huang, W., & Cao, L. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.09.009 · Cited by 54
“rAAV vectors primarily remain episomal in the nucleus of transduced cells, and random integration of AAV vectors into host DNA are low-frequency events,(1) although the integrations and subsequent toxicity have been observed in mouse models.(53) AAVs have low immunogenicity and can transduce both dividing and non-divi…”
BackgroundChen, X., Dong, T., Hu, Y.-H., Pace, R. D., Mattera, R., Eberhardt, K., Ziegler, M., Pirovolakis, T., Şahin, M., Bonifacino, J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164575 · Cited by 41
“One large-scale study in mice found no evidence for tumorigenesis following AAV administration (48), despite other studies having found evidence for limited AAV integration (49, 50).”
BackgroundTherapeutic homology-independent targeted integration in retina and liver
Tornabene, P., Ferla, R., Llado-Santaeularia, M., Centrulo, M., Dell’Anno, M., Esposito, F., Marrocco, E., Pone, E., Minopoli, R., Iodice, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29550-8 · Cited by 44
Cunningham, S. C., Siew, S., Hallwirth, C. V., Bolitho, C., Sasaki, N., Garg, G., Michael, I. P., Hetherington, N. A., Carpenter, K. H., de Alencastro, G., et al. (2015) · Hepatology · doi:10.1002/hep.27842 · Cited by 49
“S3), which is consistent with observations by others following AAV integration in the neonatal liver.(29) Importantly, genes implicated as drivers of hepatocellular carcinoma(30) were not among these, nor was integration overrepresented at the Rian-Mirg locus linked to AAV integration–induced hepatocellular carcinoma(…”
ResultRecombinant Antibody Fragments for Neurodegenerative Diseases
Manoutcharian, K., Pérez-Garmendia, R., & Gevorkian, G. (2016) · Current Neuropharmacology · doi:10.2174/1570159x01666160930121647 · Cited by 51
“Careful design of safer AAV vectors and development of novel methods of recombinant antibody delivery merit further research [69].”
BackgroundKonkle, B. A., Pierce, G. F., Coffin, D., Naccache, M., Clark, R. C., George, L. A., Iorio, A., O’Mahony, B., Pipe, S. W., Skinner, M. W., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15023 · Cited by 50
Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia
Pierce, G. F., Fong, S., Long, B. R., & Kaczmarek, R. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.12.005 · Cited by 50
Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec
Anguela, X. M., & High, K. A. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023010511 · Cited by 54
A universal system to select gene-modified hepatocytes in vivo
Nygaard, S. C., Barzel, A., Haft, A., Major, A. M., Finegold, M. J., Kay, M. A., & Grompe, M. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad8166 · Cited by 48
Adeno-associated virus finds its disease
Russell, D. W., & Grompe, M. (2015) · Nature Genetics · doi:10.1038/ng.3407 · Cited by 48
Liver‐directed gene therapy for inherited metabolic diseases
Baruteau, J., Brunetti‐Pierri, N., & Gissen, P. (2024) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12709 · Cited by 49
Improving Molecular Therapy in the Kidney
Rubin, J. D., & Barry, M. A. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-020-00467-6 · Cited by 50
Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain
Pardridge, W. M. (2020) · Frontiers in Medical Technology · doi:10.3389/fmedt.2020.602236 · Cited by 46
“The dose of scAAV9 administered to humans, 2× 1014 vg/kg (10), is the same dose that causes a high incidence of delayed onset of hepatocellular carcinoma in mice (12).”
BackgroundMattar, C. N., Wong, A. M. S., Hoefer, K., Alonso-Ferrero, M. E., Buckley, S. M. K., Howe, S. J., Cooper, J. D., Waddington, S. N., Chan, J. K. Y., & Rahim, A. A. (2015) · The FASEB Journal · doi:10.1096/fj.14-269092 · Cited by 46
“(19) have robustly demonstrated the importance of longer-term observation when using systemically administered AAV vectors during the neonatal period to monitor for hepatic genotoxicity.”
BackgroundPierce, G. F., & Iorio, A. (2018) · Haemophilia · doi:10.1111/hae.13489 · Cited by 47
Ago, Y., Rintz, E., Musini, K. S., Ma, Z., & Tomatsu, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021113 · Cited by 48
Development challenges associated with rAAV-based gene therapies
Bolt, M. W., Brady, J. T., Whiteley, L. O., & Khan, K. N. M. (2021) · The Journal of Toxicological Sciences · doi:10.2131/jts.46.57 · Cited by 49
Safety questions for AAV gene therapy
Venditti, C. P. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-00756-9 · Cited by 46
Self-citationGene regulation technologies for gene and cell therapy
Butterfield, G. L., Reisman, S. J., Iglesias, N., & Gersbach, C. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.004 · Cited by 48
“25 To address the challenges posed by semi-random AAV integration, investigators are increasingly exploring targeted genomic integration strategies.”
Karumuthil-Melethil, S., Nagabhushan Kalburgi, S., Thompson, P., Tropak, M., Kaytor, M. D., Keimel, J. G., Mark, B. L., Mahuran, D., Walia, J. S., & Gray, S. J. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.013 · Cited by 43
“Furthermore, some studies have reported incidence of liver tumors with intravenous delivery of AAV9 into neonates.(14,30,31) A liver-detargeted version of AAV9 with comparable levels of brain and spinal cord transduction could be a safer reagent to treat neurological disorders.”
CRISPR/Cas9: at the cutting edge of hepatology
Pankowicz, F. P., Jarrett, K. E., Lagor, W. R., & Bissig, K. (2017) · Gut · doi:10.1136/gutjnl-2016-313565 · Cited by 47
Adeno-Associated Virus-Based Gene Therapy for Lifelong Correction of Genetic Disease
Brommel, C. M., Cooney, A. L., & Sinn, P. L. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.138 · Cited by 47
“These integrations were mapped to the Rian locus and associated with age, dose, promoter/ enhancer selection, and capsid choice.(88) In total, AAV2 posed the greatest risk of insertional mutagenesis.”
MethodTargeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma
Wang, Y., Huang, P.-P., Zhang, R., Ma, B.-Y., Zhou, X.-M., & Sun, Y.-F. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i1.326 · Cited by 44
Fader, K. A., Pardo, I. D. R., Kovi, R. C., Somps, C. J., Wang, H. H., Vaidya, V. S., Ramaiah, S. K., & Sirivelu, M. P. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.017 · Cited by 41
“Moreover, neonatal mice are reported to develop hepatocellular carcinoma following AAV integration at the RNA imprinted and accumulated in nucleus (Rian) locus.(15,16) However, insertional mutagenesis has not been observed in adult mice or other nonclinical species, suggesting a species- and age-dependent mechanism.”
BackgroundInfluentialProgressive lung fibrosis: reprogramming a genetically vulnerable bronchoalveolar epithelium
Bridges, J. P., Vladar, E. K., Kurche, J. S., Krivoi, A., Stancil, I. T., Dobrinskikh, E., Hu, Y., Sasse, S. K., Lee, J. S., Blumhagen, R. Z., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci183836 · Cited by 46
“However, the main barriers for epigenetic reprogramming to become a therapeutic target for IPF remain efficiency of in vivo construct delivery into cell types of interest and the risk of side effects and nonspecific activity (252, 269, 270).”
Pardridge, W. M. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114234 · Cited by 44
Adeno-associated virus infection and its impact in human health: an overview
Sant’Anna, T. B. F., & Araujo, N. M. (2022) · Virology Journal · doi:10.1186/s12985-022-01900-4 · Cited by 40
Guenzel, A. J., Collard, R., Kraus, J. P., Matern, D., & Barry, M. A. (2015) · Human Gene Therapy · doi:10.1089/hum.2014.126 · Cited by 42
“More recently, liver cancers have been observed after neonatal AAV8 treatment of mouse models of methylmalonic acidemia (MMA).(46) This is concerning as the MMA results from mutations in the enzyme methylmalonyl CoA mutase, the metabolic step immediately after PCC.”
Ilyinskii, P. O., Michaud, A. M., Rizzo, G. L., Roy, C. J., Leung, S. S., Elkins, S. L., Capela, T., Chowdhury, A., Li, L., Chandler, R. J., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.06.015 · Cited by 39
Self-citationRegulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies
Moffit, J. S., Blanset, D. L., Lynch, J. L., MacLachlan, T. K., Meyer, K. E., Ponce, R. A., & Whiteley, L. O. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.090 · Cited by 45
“19 Accumulation of AAV integration into the Rian locus and increased HCC incidence in mouse models were subsequently replicated, with increased risk linked to hepatic inflammation, hepatocellular turnover, vector design, and dosing.”
BackgroundmRNA and gene editing: Late breaking therapies in liver diseases
Zabaleta, N., Torella, L., Weber, N. D., & González‐Aseguinolaza, G. (2022) · Hepatology · doi:10.1002/hep.32441 · Cited by 40
“[51] This method theoretically avoids two major safety issues associated with the use of nucleases and AAVs for gene delivery: (1) the off- target modifications by nucleases[49] and (2) the random integration of AAV genomes leading to transactivation of oncogenic genes.[52] However, the low editing efficiency limits t…”
MethodOsmon, K. J. L., Woodley, E., Thompson, P., Ong, K., Karumuthil‐Melethil, S., Keimel, J. G., Mark, B. L., Mahuran, D. J., Gray, S. J., & Walia, J. S. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.015 · Cited by 43
“Associated with a high liver uptake is an increased probability of hepatocellularnodule/tumor formation when administered to neonatal mice.(14,23) The recent advances in AAV technology have enabled the creation and testing of chimeric AAV capsids combining aspects from multiple serotypes in order to achieve greater ta…”
Gene therapy for metabolic diseases
Chandler, R. J., & Venditti, C. P. (2016) · Translational Science of Rare Diseases · doi:10.3233/trd-160007 · Cited by 42
“However, two independent studies have observed an increased incidence of hepatic carcinoma after a neonatal injection of a high dose of AAV in mice with Sly disease (MPS VII) [59] and methylmalonic acidemia [60] and data suggests that insertional mutagenesis may have been the cause.”
Self-citationConsiderations for Preclinical Safety Assessment of Adeno-Associated Virus Gene Therapy Products
Assaf, B. T., & Whiteley, L. O. (2018) · Toxicologic Pathology · doi:10.1177/0192623318803867 · Cited by 39
Progress and challenges in development of new therapies for urea cycle disorders
Soria, L. R., Mew, N. A., & Brunetti‐Pierri, N. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz140 · Cited by 39
Nault, J.-C., Mami, I., La Bella, T., Datta, S., Imbeaud, S., Franconi, A., Mallet, M., Couchy, G., Letouzé, E., Pilati, C., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.47 · Cited by 39
AAV-Mediated Gene Delivery to the Liver: Overview of Current Technologies and Methods
Palaschak, B., Herzog, R. W., & Markusic, D. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9139-6_20 · Cited by 40
AAV9-mediated FIG4 delivery prolongs life span in Charcot-Marie-Tooth disease type 4J mouse model
Presa, M. F., Bailey, R. M., Davis, C., Murphy, T. C., Cook, J., Walls, R., Wilpan, H., Bogdanik, L. P., Lenk, G. M., Burgess, R. W., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci137159 · Cited by 40
“In the neonatal mouse genome, AAV9 vectors are prone to integration in the Rian locus (16).”
BackgroundMethodResultInfluentialMartins, K. M., Breton, C. A., Zheng, Q., Zhang, Z., Latshaw, C., Greig, J. A., & Wilson, J. M. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.134 · Cited by 38
Hadi, M., Allela, O. Q. B., Jabari, M., Jasoor, A. M., Naderloo, O., Yasamineh, S., Gholizadeh, O., & Kalantari, L. (2024) · Virology Journal · doi:10.1186/s12985-024-02286-1 · Cited by 37
“Research by Chandler et al. revealed that AAV often integrates into highly active liver genes [152].”
MethodDeveloping Modern Pain Therapies
Manion, J., Waller, M. A., Clark, T., Massingham, J. N., & Neely, G. G. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01370 · Cited by 39
Liver directed adeno‐associated viral vectors to treat metabolic disease
Chuecos, M. A., & Lagor, W. R. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12637 · Cited by 36
“151 Integrations into the Rian locus were associated with hepatocellular carcinoma, an effect that was dependent on age of delivery, dosage, and promoter strength.”
BackgroundFinal Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B
Pipe, S. W., Miesbach, W., Recht, M., Leebeek, F. W. G., Key, N. S., Castaman, G., Lattimore, S., Coppens, M., Quellec, S. L., Mahajan, V., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2514332 · Cited by 41
Establishment of two quantitative nested qPCR assays targeting the human EPO transgene
Neuberger, E. W. I., Perez, I. C., Guiner, C. L., Moser, D., Ehlert, T., Allais, M., Moullier, P., Simon, P. D., & Snyder, R. O. (2016) · Gene Therapy · doi:10.1038/gt.2016.2 · Cited by 35
AAV Infection: Protection from Cancer
Srivastava, A., & Carter, B. J. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.147 · Cited by 36
“Similarly, as reported by Chandler et al.(52) the rAAV genome was found to be integrated most commonly in the albumin gene in mouse livers, whereas no integration of the wt AAV genome was detected in this locus in the human genome in any of the HCC patients in the studies reported by Nault et al.”
MethodChan, J. K. Y., Gil-Fariña, I., Johana, N. B., Rosales, C., Tan, Y. W., Ceiler, J., McIntosh, J., Ogden, B. E., Waddington, S. N., Schmidt, M., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201801391r · Cited by 37
“Our data revealed no adverse events derived from direct AAV toxicity or insertional mutagenesis during the 4-yr surveillance in contrast to recent studies thatused logfold higher doses (49, 69).”
ResultLysosomal Abnormalities in Cardiovascular Disease
Chi, C., Riching, A. S., & Song, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030811 · Cited by 40
“Moreover, AAV infection has been shown to cause hepatic toxicity and hepatocellular carcinoma in mice [70,71].”
BackgroundOrganoids and microphysiological systems: Promising models for accelerating AAV gene therapy studies
Ramamurthy, R. M., Atala, A., Porada, C. D., & Almeida-Porada, G. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1011143 · Cited by 36
Obstacles and future of gene therapy for hemophilia
Arruda, V. R., & Samelson-Jones, B. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1069179 · Cited by 33
“Notably, the use of hAAT promoter, which is present in most of the ongoing clinical trials, is among the safest vector system evaluated [51].”
BackgroundHarrington, E. A., Sloan, J. L., Manoli, I., Chandler, R. J., Schneider, M., McGuire, P. J., Calcedo, R., Wilson, J. M., & Venditti, C. P. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.092 · Cited by 34
“The unexpected lack of NAbs against AAV in this patient population has encouraging implications for systemic gene delivery as a treatment for mut MMA.”
BackgroundSelf-citationBočkor, L., Bortolussi, G., Iaconcig, A., Chiaruttini, G., Tiribelli, C., Giacca, M., Benvenuti, F., Zentilin, L., & Muro, A. F. (2017) · Gene Therapy · doi:10.1038/gt.2017.75 · Cited by 32
Neuroepithelial Tumor with AAV Integration after Intracisternal Magna Vector Delivery
Ahrens‐Nicklas, R. C., Kotch, C., Roche, A. M., Everett, J. K., Reddy, S., Santi, M., Madsen, P. J., Martos-Rus, C., Yrigollen, C. M., Small, J. C., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2601608 · Cited by 35
Hemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche, T., & Chuah, M. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.116 · Cited by 32
Strategies to improve safety profile of AAV vectors
Suoranta, T., Laham-Karam, N., & Ylä‐Herttuala, S. (2022) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2022.1054069 · Cited by 33
“This was speculated to be due to the increased activation of nearby genes by CBA and TBG promoters (Chandler et al., 2015).”
BackgroundWaddington, S. N., Peranteau, W. H., Rahim, A. A., Boyle, A. K., Kurian, M. A., Gissen, P., Chan, J. K. Y., & David, A. L. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12659 · Cited by 31
“104 The leukemias associated with gene-modified hematopoietic stem cell transplantation in X-SCID patients were caused, in several cases, by vector integration near and upregulation of the LMO2 proto-oncogene.”
BackgroundClinical and Translational Landscape of Viral Gene Therapies
Yudaeva, A., Kostyusheva, A. P., Kachanov, A., Brezgin, S. A., Ponomareva, N., Parodi, A., Pokrovsky, V. S., Lukashev, A. N., Chulanov, V., & Kostyushev, D. S. (2024) · Cells · doi:10.3390/cells13221916 · Cited by 32
Mesenchymal stem cells as carrier of the therapeutic agent in the gene therapy of blood disorders
Shomali, N., Gharibi, T., Vahedi, G., Mohammed, R. N., Mohammadi, H., Salimifard, S., & Marofi, F. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29324 · Cited by 30
Gene therapy for urea cycle defects: An update from historical perspectives to future prospects
Duff, C. E., Alexander, I. E., & Baruteau, J. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12609 · Cited by 32
“59 AAV-mediated gene transfer relies predominantly on episomes, circular double-stranded DNA molecules pre-sent in the nucleus, which are diluted and lost during cell division 50 (Figure 2).”
BackgroundMethodGene therapy decreases seizures in a model of Incontinentia pigmenti
Dogbevia, G., Töllner, K., Körbelin, J., Bröer, S., Ridder, D. A., Graßhoff, H., Brandt, C., Wenzel, J., Straub, B. K., Trepel, M., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24981 · Cited by 32
Molecular biology and gene therapy for glycogen storage disease type Ib
CHOU, J. Y., Cho, J., Kim, G., & Mansfield, B. C. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-018-0180-5 · Cited by 31
“2b) (Hiraiwa et al. 1999; Chen et al. 2002, 2008a, b).”
Ginocchio, V. M., Ferla, R., Auricchio, A., & Brunetti‐Pierri, N. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.151 · Cited by 30
“26 29 Moreover, AAV5 integration analysis in NHP and patients enrolled in a gene therapy clinical trial for acute intermittent porphyria (AIP) 30 did not reveal integration clusters or events in genes previously reported in HCC.”
Fakhiri, J., & Grimm, D. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.005 · Cited by 30
Intégration des vecteurs AAV et mutagenèse insertionnelle
Rossi, A., & Salvetti, A. (2016) · médecine/sciences · doi:10.1051/medsci/20163202010 · Cited by 33
Lee, H., Jiang, D., & Pardridge, W. M. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00310 · Cited by 33
Cabrera-Pérez, R., Vila‐Julià, F., Hirano, M., Mingozzi, F., Torres‐Torronteras, J., & Martí, R. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.217 · Cited by 32
“In a recent study, AAT and TBG promoters both induced AAV integration in the Rian locus in mice, but use of the AAT enhancer/promoter did not lead to overexpression of local genes, unlike the TBG promoter.(40) It is worth mentioning that TYMP can act as a suicide gene in TYMP-expressing tumors when capecitabine is use…”
BackgroundA primer to gene therapy: Progress, prospects, and problems
Zittersteijn, H. A., Gonçalves, M. A. F. V., & Hoeben, R. C. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12270 · Cited by 32
“The potential genotoxicity of AAV vectors has also been a subject of controversy due to several liver-directed gene therapy experiments in rodents in which AAVs were implied in the induction of hepatocellular carcinoma (HCC) upon genomic integration.(88,89) However, the limited amount of human clinical data does not s…”
Ethical Challenges and Controversies in the Practice and Advancement of Gene Therapy
Ansah, E. O. (2022) · Advances in Cell and Gene Therapy · doi:10.1155/2022/1015996 · Cited by 31
“A study in an animal model shows that the integration of AAV into chromosome 19 could possibly result in genotoxic effects, leading to neoplastic transformations that are prone to tumor development [25].”
BackgroundChen, S. K., Hawley, Z. C. E., Zavodszky, M. I., Hana, S., Ferretti, D., Grubor, B., Hawes, M. C., Xu, S., Hamann, S., Marsh, G., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102057 · Cited by 28
“18,42 Overall, further optimization of pri-miRNA scaffolds, among other factors, is necessary for the development of ideal AAV-amiR-SOD1 gene therapy in the clinic.”
BackgroundAdvances in understanding disease mechanisms and potential treatments for Crigler–Najjar syndrome
Bortolussi, G., & Muro, A. F. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1495558 · Cited by 31
Wang, H., Liu, Z., Li, C., Gil, S., Papayannopoulou, T., Doering, C. B., & Lieber, A. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000706 · Cited by 28
The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy
Puzzo, F., & Kay, M. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.041 · Cited by 31
Sabbata, G. D., Boisgérault, F., Guarnaccia, C., Iaconcig, A., Bortolussi, G., Collaud, F., Ronzitti, G., Sola, M. S., Vidal, P., Rouillon, J., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.11.005 · Cited by 26
“Factors such as the total vector dose and the promoter choice may affect the genotoxicity risk of AAV vectors.(19) In effect, the presence of the chicken b-actin (CBA) promoter or the liver-specific TBG promoter, commonly used in AAV vectors, results in the development of HCC when delivered in”
BackgroundPagant, S., Huston, M. W., Moreira, L., Gan, L., Martin, S. S., Sproul, S., Holmes, M. C., Meyer, K. E., Wechsler, T., Desnick, R. J., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.03.018 · Cited by 26
Dasari, B., Cashman, S. M., & Kumar‐Singh, R. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.06.004 · Cited by 26
Gene Therapy for Hemophilia: Progress to Date
Chapin, J. C., & Monahan, P. E. (2017) · BioDrugs · doi:10.1007/s40259-017-0255-0 · Cited by 26
“in mouse models of other diseases [150] and large studies using different AAV serotypes [151].”
BackgroundHaemophilia gene therapy: From trailblazer to gamechanger
Evens, H., Chuah, M., & VandenDriessche, T. (2018) · Haemophilia · doi:10.1111/hae.13494 · Cited by 26
Gene therapies for mucopolysaccharidoses
Rossi, A., & Brunetti‐Pierri, N. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12626 · Cited by 25
“60 Moreover, clonal integration of wild-type AAV2 has been found in a small percentage of HCC samples.”
BackgroundGene therapy for organic acidemias: Lessons learned from methylmalonic and propionic acidemia
Chandler, R. J., & Venditti, C. P. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12665 · Cited by 24
“48 Detailed studies have subsequently revealed that the mechanisms underlying AAV genotoxicity after neonatal gene therapy largely derive from the inclusion of viral enhancers and strong promoters in the AAV trans-gene cassettes, with subsequent transcriptional transactivation after integration,…”
BackgroundSelf-citationKhoja, S., Nitzahn, M., Hermann, K. J., Truong, B., Borzone, R., Willis, B., Rudd, M., Palmer, D. J., Ng, P., Brunetti‐Pierri, N., et al. (2018) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2018.04.001 · Cited by 24
“Recent data suggesting, at least in mice, an association between AAV and hepatocellular carcinoma does raise some concern about genotoxicity and safety for AAV hepatic gene therapy in neonates and children [38].”
BackgroundNuclease-Mediated Gene Therapies for Inherited Metabolic Diseases of the Liver.
Te, B., Anglin, C. M., Bridges, P. H., & Cottle, R. N. (2017) · PubMed Central · Cited by 33
Hemophilia gene therapy: ushering in a new treatment paradigm?
George, L. A. (2021) · Hematology · doi:10.1182/hematology.2021000254 · Cited by 25
Therapeutic application of the CRISPR system: current issues and new prospects
Lee, M., & Kim, S. (2019) · Human Genetics · doi:10.1007/s00439-019-02028-2 · Cited by 25
Esposito, F., Dell’Aquila, F., Rhiel, M., Auricchio, S., Chmielewski, K. O., Andrieux, G., Ferla, R., Horrach, P. S., Padmanabhan, A., Cunto, R. D., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101619 · Cited by 32
AAV8 Gene Therapy Rescues the Newborn Phenotype of a Mouse Model of Crigler–Najjar
Greig, J. A., Nordin, J. M. L., Draper, C., Bell, P. L., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.185 · Cited by 25
“22,24 Therefore, this risk may be mitigated by using the lowest possible dose for rescue of the newborn phenotype.”
Efficacy and costs of spinal muscular atrophy drugs
Darrow, J. J., Sharma, M., Shroff, M., & Wagner, A. K. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay9648 · Cited by 23
“The delivery vector for the therapeutic gene, an adeno-associated virus, is not expected to insert into the human genome, thus minimizing the risk of treatmentrelated malignancy, but concerns remain following rodent studies linking adenoassociated viral vectors with hepatocellular carcinoma (7).”
BackgroundRathbone, T., Ates, I., Fernando, L. P., Addlestone, E., Lee, C. M., Richards, V. P., & Cottle, R. N. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0134 · Cited by 24
“Insertional mutagenesis of AAV vectors caused hepatocellular carcinoma in neonatal mice.(17,18) Because DNA cargo delivered by”
BackgroundFludarabine increases nuclease-free AAV- and CRISPR/Cas9-mediated homologous recombination in mice
Tsuji, S., Stephens, C. J., Bortolussi, G., Zhang, F., Baj, G., Jang, H., de Alencastro, G., Muro, A. F., Pekrun, K., & Kay, M. A. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01240-2 · Cited by 24
Oziolor, E. M., Kumpf, S. W., Qian, J., Gosink, M. M., Sheehan, M. J., Rubitski, D. M., Newman, L., Whiteley, L. O., & Lanz, T. A. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.04.009 · Cited by 23
“A finding of HCC caused by a recombinant AAV integration into the Rian locus has been observed in mice following neonatal injection,(6) a pattern that has been replicated using other AAV serotypes with differing cargos.(7) No Rian locus integration or HCC have been reported in adult mice following recombinant AAV admi…”
ResultLiver-directed gene therapy for murine glycogen storage disease type Ib
Kwon, J. H., Lee, Y., Cho, J., Kim, G., Anduaga, J., Starost, M. F., Mansfield, B. C., & CHOU, J. Y. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx325 · Cited by 22
Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY
Doshi, B. S., Arruda, V. R., & Arruda, V. R. (2020) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2020.069 · Cited by 25
Buscara, L., Gross, D., & Danièle, N. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040258 · Cited by 23
Viral gene therapy for paediatric neurological diseases: progress to clinical reality
Privolizzi, R., Chu, W. S., Tijani, M., & Ng, J. (2021) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.14885 · Cited by 21
“Another safety concern is potential integration as wildtype AAV integrates into host genome.(46) While rAAV primarily remains episomal, integration events have been observed in mice after neonatal intravenous rAAV.”
BackgroundChapdelaine, P., Gérard, C., Sanchez, N., Cherif, K., Rousseau, J., Ouellet, D. L., Jauvin, D., & Tremblay, J. P. (2016) · Gene Therapy · doi:10.1038/gt.2016.36 · Cited by 24
Bazick, H., Mao, H., Niehaus, J. K., Wolter, J. M., & Zylka, M. J. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.09.032 · Cited by 20
In vivo genome editing at the albumin locus to treat methylmalonic acidemia
Schneller, J. L., Lee, C. M., Venturoni, L. E., Chandler, R. J., Li, A., Myung, S., Cradick, T. J., Hurley, A. E., Lagor, W. R., Bao, G., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.11.004 · Cited by 20
“Both approaches have intrinsic limitations related to the transient nature of expression, untoward immune reactions that might limit re-administration and, in the case of rAAV, the potential for genotoxicity caused by random integration of vectors containing strong promoter elements.(15) A distinct strategy to circumv…”
Self-citation
Metadata
- Authors
- Chandler, R. J., LaFave, M. C., Varshney, G. K., Trivedi, N. S., Carrillo-Carrasco, N., Senac, J. S., Wu, W., Hoffmann, V., Elkahloun, A. G., Burgess, S. M., & Venditti, C. P.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2015-01-20
- Volume
- 125
- Issue
- 2
- Pages
- 870-880
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4319425
- OpenAlex
- W2133112334
- Cited by
- 403
- References
- 63
- Citations by year
- 2026: 28 · 2025: 42 · 2024: 40 · 2023: 38 · 2022: 36 · 2021: 32 · 2020: 45 · 2019: 30 · 2018: 26 · 2017: 32 · 2016: 31 · 2015: 22
- FWCI
- 25.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Human Genome Research Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- adeno-associated virus, gene therapy vectors, hepatocellular carcinoma, genotoxicity, AAV integration, microRNA overexpression, RTL1, vector dose
- MeSH terms
- Dependovirus, Animals, Genetic Vectors, Carcinoma, Hepatocellular, Liver Neoplasms, Mice, Mutant Strains, Pregnancy Proteins, Transduction, Genetic, Genetic Therapy, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.